Engineered tRNA to treat inherited eye diseases
Anticodon Engineered tRNA for the Treatment of Hereditary Eye Disease
This project uses an engineered tRNA that can bypass premature genetic 'stop' signals to help people with inherited eye diseases caused by nonsense mutations.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11249608 on NIH RePORTER |
What this research studies
Scientists are testing engineered transfer RNAs designed to read through premature ‘stop’ signals (nonsense mutations) that break genes causing inherited eye disorders. They will study a specific engineered tRNA (Arg-TGA ACE-tRNA) in specially bred mice that carry it throughout their bodies to see how it works in retinal, corneal, and other eye cell types. The team will measure whether full-length proteins are restored, look for improvements in cellular and vision-related measures, and check safety in the eye and whole animal. Findings will determine whether this approach could move toward patient-directed therapies for people with nonsense-mutation eye disease.
Who could benefit from this research
Good fit: People with inherited eye conditions caused by nonsense (premature stop codon) mutations—such as certain retinal degenerations, corneal dystrophies, congenital cataract, or hereditary glaucoma—would be the most relevant candidates.
Not a fit: Patients whose vision problems are caused by other types of mutations, non-genetic eye disease, or long-standing irreversible damage are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could restore missing proteins and potentially prevent or improve vision loss in people with inherited eye diseases caused by nonsense mutations.
How similar studies have performed: Laboratory and animal studies of suppressor tRNAs and related readthrough approaches have shown promising protein rescue, but human data are very limited and the approach remains largely preclinical.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Anderson, Michael G — University of Iowa
- Study coordinator: Anderson, Michael G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.